SCHEMBL7680189

SCHEMBL7680189

N#Cc1ccc(Cc2ccccn2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
TRPV4 Q9HBA0 1/20 0.44
MET P08581 1/20 0.42
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HBB P68871 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP11B1 P15538 6/20 0.41
CYP11B2 P19099 6/20 0.41
GPR52 Q9Y2T5 1/20 0.41
CXCR3 P49682 1/20 0.40
DAO P14920 2/20 0.39
GRM4 Q14833 1/20 0.39
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3435072 0.79 CXCR3 (0.39) TRPV4GPR52CXCR3KMT2A
SCHEMBL24872449 0.79 TRPV4 (0.61) TRPV4CYP11B1CYP11B2GPR52DAO
SCHEMBL3305103 0.78 TRPV4 (0.52) TRPV4HPGDTSHRCYP11B1CYP11B2
SCHEMBL4325031 0.77 MAOB (0.48) TRPV4MAPTSMN1; SMN2CYP11B1CYP11B2
SCHEMBL7674444 0.77 L3MBTL1 (0.50) L3MBTL1MAPTTSHRALDH1A1HRH1
SCHEMBL30063557 0.76 L3MBTL1 (0.51) L3MBTL1MAPTALOX15SMN1; SMN2ALDH1A1
SCHEMBL12812248 0.75 TRPV4 (0.49) L3MBTL1TRPV4CYP11B1CYP11B2GPR52
SCHEMBL30062621 0.75 L3MBTL1 (0.47) L3MBTL1MAPTCYP11B2DAOGRM4
SCHEMBL28095397 0.74 L3MBTL1 (0.59) L3MBTL1MAPTSMN1; SMN2CYP11B1CYP11B2
SCHEMBL7673699 0.73 NR1D1 (0.48) TRPV4METHPGDALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037888-A1 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease MERCK & CO., INC. 2002-03-28 US disclosed
US-6284755-B1 Inhibitors of prenyl-protein transferase MERCK & CO., INC. 2001-09-04 US disclosed
WO-2000034437-A2 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037888-A1 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease FNTA, PKD1, FNTB L3MBTL1 2951/4885TRPV4 1403/4885MET 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.